Dietary supplement

EQS-News: Exasol publishes preliminary figures for the first half of 2023, outlook confirmed

Retrieved on: 
Tuesday, August 8, 2023

Exasol publishes preliminary figures for the first half of 2023, outlook confirmed

Key Points: 
  • Exasol publishes preliminary figures for the first half of 2023, outlook confirmed
    The issuer is solely responsible for the content of this announcement.
  • Exasol publishes preliminary figures for the first half of 2023, outlook confirmed
    - Cash and cash equivalents at EUR 11.7 million as of June 30, 2023
    Nuremberg, 8.
  • "Several major customer projects that we expected to close in the first half of the year were postponed to the second half.
  • As a result, overall revenue development in the first half of the year fell short of our expectations," explains Jörg Tewes, CEO of Exasol AG.

What is POTS? And how is it related to long COVID?

Retrieved on: 
Tuesday, August 8, 2023

But during the pandemic, we’ve been learning about the strong similarities with long COVID.

Key Points: 
  • But during the pandemic, we’ve been learning about the strong similarities with long COVID.
  • In fact, our recent research shows more than three-quarters of people with long COVID we studied had POTS.
  • À lire aussi :
    When does COVID become long COVID?

What triggers it?

    • Then came the pandemic, with almost 800 million people infected so far with SARS-CoV-2, the virus that causes COVID.
    • The World Health Organization says 10-20% of people infected with COVID are likely to develop long COVID – when unexplained symptoms persist three months or more after the infection.

What we and others have found

    • The people in our study either attended a specialist cardiology clinic for people with POTS or long COVID, or came via a long COVID support group on social media.
    • So we cannot generalise our results to people managing their long COVID at home or with their GP.
    • Earlier this year, a review said about 30% of people with people with “highly symptomatic” long COVID also had POTS.

What happens if you have POTS?

    • This, or another trigger, affects the autonomic nervous system.
    • Even if the autonomic nervous system is marginally disturbed, it leads to the physiological equivalent of anarchy.

A long path to diagnosis

    • Diagnosis can take years.
    • In our submission to the parliamentary inquiry into long COVID, we shared the experiences of people with POTS symptoms and their frustration at the lack of recognition by the medical profession.
    • À lire aussi :
      We got some key things wrong about long COVID.

We can do better

    • Although many people with POTS report they were referred to multiple specialists before they were diagnosed, this is not always necessary.
    • GPs can ask you to do a ten-minute standing test to help diagnose it.
    • They can also exclude other common causes of POTS symptoms, such as lung and heart conditions.
    • À lire aussi :
      What should my heart rate be and what affects it?

How about referral?

    • There are no specialised clinics for POTS in public hospitals.
    • For more information about the condition, see the Australian POTS Foundation website, which also lists doctors and allied health professionals who are “POTS aware”.
    • Marie-Claire Seeley receives funding from The Australian Government Research Training Scholarship and Standing up to POTS .

Graminex® Rye Pollen Achieves Novel Food Registration in China and Appoints Guangzhou Narnia Biotechnology as Their Authorized Distribution Partner

Retrieved on: 
Tuesday, August 8, 2023

Graminex® announced today that it has achieved novel food registration in China for Rye Pollen and appointed Guangzhou Narnia Biotechnology as its distribution partner in China.

Key Points: 
  • Graminex® announced today that it has achieved novel food registration in China for Rye Pollen and appointed Guangzhou Narnia Biotechnology as its distribution partner in China.
  • Graminex®, based in the United States, is the exclusive grower and manufacturer of rye pollen and a leader in the international dietary supplement industry, with products sold in more than 47 countries.
  • Guangzhou Narnia Biotech will represent Graminex® Rye Pollen active ingredients, as well as the dietary supplements, primarily focusing on the areas of prostate health, women’s health, and liver support.
  • I am confident that through their expertise and attention to product safety and quality assurance, they are the right distribution partner for Graminex in China.”

Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 7, 2023

“Our strong second quarter 2023 results continue to drive the Company forward,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “Our strong second quarter 2023 results continue to drive the Company forward,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • The Company manufactured approximately 48 million doses in the second quarter 2023, compared to 47 million in the second quarter 2022.
  • Total reported revenues were $13.2 million in the second quarter 2023, compared to $13.3 million in the second quarter 2022.
  • Aquestive is updating its full-year 2023 financial guidance based on second quarter 2023 results and updated outlook for the remainder of 2023.

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 7, 2023

R&D Expenses: R&D expenses were $101.6 million for the second quarter of 2023, compared to $123.2 million for the second quarter of 2022.

Key Points: 
  • R&D Expenses: R&D expenses were $101.6 million for the second quarter of 2023, compared to $123.2 million for the second quarter of 2022.
  • G&A Expenses: General and administrative expenses were $19.0 million for the second quarter of 2023, compared to $26.3 million for the second quarter of 2022.
  • Collaboration Expense: Collaboration expense, net, was $44.6 million for the second quarter of 2023, compared to $33.9 million for the second quarter of 2022.
  • Net Loss: Net loss was $77.7 million for the second quarter of 2023, compared to a net loss of $185.8 million for the second quarter of 2022.

$11.93 Billion Urological Disorders Drugs Market Analysis, 2023-2028: Industry Flourishing with Advanced Therapies and Targeted Treatments on the Rise - ResearchAndMarkets.com

Retrieved on: 
Monday, August 7, 2023

The Global Urological Disorders Drugs Market is experiencing rapid growth and is estimated to be valued at USD 8.94 billion in 2023.

Key Points: 
  • The Global Urological Disorders Drugs Market is experiencing rapid growth and is estimated to be valued at USD 8.94 billion in 2023.
  • Additionally, changing lifestyles, dietary habits, and exposure to environmental toxins contribute to the increasing prevalence of urological disorders.
  • Despite these challenges, there are significant opportunities for growth in the urological disorders drugs market.
  • Overall, the global urological disorders drugs market is a promising and dynamic market with substantial growth potential, driven by the increasing prevalence of urological disorders and the adoption of advanced treatment options.

Exercising during a hospital stay linked with faster recovery – new research

Retrieved on: 
Monday, August 7, 2023

Our latest study shows that physical activity may help to counteract the effects of bed rest.

Key Points: 
  • Our latest study shows that physical activity may help to counteract the effects of bed rest.
  • We found that even just 25 minutes a day of walking while in hospital can significantly speed up recovery for older adults – and it may also prevent new hospital stays in the future.
  • This suggests physical activity may protect against the harmful effect of too much bed rest during hospital stays.
  • Other studies have also shown the benefits of physical activity during a hospital stay.

The importance of movement

    • This leads to deconditioning, loss of strength, and ultimately a reduced ability to do daily tasks independently.
    • Prolonged bed rest also decreases blood flow and lung capacity and increases the risk of deep vein thrombosis.
    • And the benefits of movement aren’t only physical.
    • There’s no “one size fits all” solution, but every movement counts.

Contacting your legislator? Cite your sources – if you want them to listen to you

Retrieved on: 
Monday, August 7, 2023

As a citizen, I would praise your sense of civic responsibility and willingness to express your opinion.

Key Points: 
  • As a citizen, I would praise your sense of civic responsibility and willingness to express your opinion.
  • I teach communication and public policy at Michigan State University and study how constitutents’ communication with lawmakers affects public policy decisions.
  • In today’s polarized political environment, is it possible to get through to policymakers from the other side?

Discounting opposing views

    • But research has also shown that policymakers engage in what’s called biased reasoning, writing off communications from constituents who do not share their policy views.
    • This discounting of constituents who disagree on policy could explain why policymakers tend to have biased perceptions of public opinion, believing the public’s attitudes to be more in line with their own positions than polling suggests.

Do your research

    • We asked a national sample of elected local policymakers – among them city council members – to evaluate a hypothetical email writer randomly assigned to express support or opposition to raising the minimum wage.
    • The survey was fielded by Civic Pulse, which specializes in samples of elected officials.
    • We anticipated, based on research on biased reasoning, that providing clear evidence that the constituent is knowledgeable about the issue would prevent biased discounting of constituent opinion.

How to not be written off

    • The effects of citing evidence are stronger than simply stating that one has read about the issue.
    • Our study is important in identifying a way constituents can avoid being written off.
    • When faced with evidence that their constituent knows the issue well, policymakers are less likely to discount their opinions.

How to be heard

    • One way to do this is by citing quality evidence to support your position.
    • When contacting a policymaker about an issue, be aware that they may discount your opinion if they disagree.

Get Thin Unveils Medical Solutions for Long-Lasting Weight Management.

Retrieved on: 
Monday, August 7, 2023

Get Thin has introduced a range of FDA-approved medications to catalyze sustainable weight loss journeys.

Key Points: 
  • Get Thin has introduced a range of FDA-approved medications to catalyze sustainable weight loss journeys.
  • At the heart of Get Thin's initiative lies its commitment to offering a lifeline to individuals struggling with weight management.
  • These medications have garnered attention not just for their efficacy in managing type 2 diabetes but for their significant impact on weight loss.
  • By leveraging the power of science and medical innovation, they have become pioneers in weight management.

ABVC Corporate Update and CEO's Letter to Shareholders

Retrieved on: 
Monday, August 7, 2023

FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. Uttam Patil.

Key Points: 
  • FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. Uttam Patil.
  • As we move into the second half of 2023, I am delighted to speak about ABVC's recent developments and plans.
  • ABVC and BioFirst Corporation expect to complete the facility's construction in Hsinchu Biomedical Science Park, Taiwan, in 2024.
  • The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials.